View Older Stories View More Recent Stories

May 15, 2018 12:45AM Novartis completes tender offer for all outstanding shares of AveXis, Inc.
May 14, 2018 05:44AM Novartis (NVS) Reports FDA Approval of Gilenya (fingolimod)
May 11, 2018 06:35PM Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
May 1, 2018 01:00AM Novartis provides update on proposed acquisition of AveXis
Apr 17, 2018 01:00AM Novartis tender offer for AveXis commences
Feb 1, 2018 04:05PM Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
Jan 26, 2018 01:02PM Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Jan 22, 2018 01:00AM Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period
Jan 16, 2018 01:21AM Novartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients
Jan 4, 2018 07:15AM Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Jan 3, 2018 07:27AM Novartis AG (NVS) Granted FDA Breakthrough Therapy designation for Kisqali for Initial Endocrine-Based Treatment in Premenopausal Women with HR+/HER2- Advanced Breast Cancer
Jan 3, 2018 07:15AM Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Dec 11, 2017 11:05AM Novartis (NVS) Reports Data from Phase II SUSTAIN Study Showing that Crizanlizumab Delayed the Time to First Sickle Cell Pain Crisis in Patients
Dec 11, 2017 11:03AM Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
Dec 7, 2017 04:13PM Novartis AG (NVS) Commences Study Evaluating Impact of Higher Dosing of Cosentyx in Patients with Ankylosing Spondylitis
Dec 7, 2017 04:02PM Novartis initiates study evaluating impact of higher dosing of Cosentyx® in patients with ankylosing spondylitis
Dec 7, 2017 06:17AM Novartis (NVS) Commences Tender Offer for Accelerator Applications (AAAP)
Dec 7, 2017 01:00AM Novartis tender offer for Advanced Accelerator Applications commences
Dec 6, 2017 01:23PM Novartis AG (NVS) Announces Data from Phase III MONALEESA-7 Trial Showing Superior Median PFS Compared to Oral Endocrine Therapy as First-Line Treatment
Dec 6, 2017 01:15PM Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to p
Nov 14, 2017 07:15AM Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
Nov 1, 2017 09:14AM Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
Oct 31, 2017 09:06AM Xenetic Biosciences (XBIO) Appoints Jeffrey Eisenberg as CEO
Oct 31, 2017 09:05AM Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer
Oct 24, 2017 08:00AM Novartis collaborates with pop icon Cyndi Lauper to release new song in honor of World Psoriasis Day
Sep 14, 2017 07:05AM TransCelerate BioPharma Grows Industry Collaboration
Jul 25, 2017 09:29AM Cryoport (CYRX) Says Novartis (NVS) Signed Agreement Contracting it Over Initial Three-year Term for Cryogenic Logistics Support of CTL019/CD19 CAR-T Cell Therapy
Jul 14, 2017 03:52PM Novartis (NVS) Confirms 5 year Data for IL-17A Inhibitor Cosentyx
Jul 14, 2017 03:51PM Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
Jun 5, 2017 04:08PM Bristol-Myers Squibb (BMY) New Collaboration WIth Novartis (NVS) To Evaluate Combo Therapy In Colorectal Cancer
May 26, 2017 04:05PM Novartis (NVS) Confirms FDA Approval for Expanded Use of Zykadia®
May 26, 2017 04:02PM Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)
May 2, 2017 09:00AM Sandoz Canada launches Sandoz Olmesartan for the treatment of high blood pressure
May 2, 2017 06:26AM Celyad (CYAD), Novartis (NVS) Enter Non-Exclusive License for Allogeneic TCR-Deficient CAR-T Cells
Apr 24, 2017 04:33PM Amgen (AMGN), Novartis (NVS) Expand Commercial Collaboration for Erenumab In Migraine
Apr 18, 2017 09:00AM Sandoz Canada launches Mosaspray(TM) in Quebec: a non-prescription mometasone nasal spray for the treatment of the symptoms of allergic rhinitis
Mar 24, 2017 05:49AM Novartis (NVS) to Help PureTech Advance Clinical Stage mTORC1 Programs
Mar 6, 2017 06:18AM Novartis (NVS) Says Extension Study of Cosentyx Shows Almost All Psoriasis Patients Regain Skin Clearance Following Treatment Pause
Mar 6, 2017 01:30AM Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
Jan 31, 2017 11:24AM Sandoz Canada launches Sandoz(R) Amphetamine XR for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Dec 9, 2016 08:30AM Novartis LEE011 (ribociclib) plus letrozole analyses show superior PFS across broad spectrum of patients in first-line HR+/HER2- advanced breast cancer versus letrozole
Nov 16, 2016 07:30AM Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer
Nov 14, 2016 07:32AM Novartis' (NVS) PKC412 NDA Granted FDA Priority Review as AML Treatment
Nov 10, 2016 08:00AM Novartis partners with prominent US health advocacy organizations to launch first social networking platform for heart failure patients and their loved ones
Nov 1, 2016 07:30AM Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer
Oct 10, 2016 06:57AM Novartis (NVS) Announces Presentation of Significant Phase III MONALEESA-2 Data at ESMO 2016
Oct 8, 2016 08:00AM Novartis breakthrough therapy LEE011 (ribociclib) plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of
Oct 3, 2016 06:36AM Novartis (NVS) Announces Strong Cosentyx Phase III SCULPTURE Trial 1 Data in Psoriasis Patients
Oct 1, 2016 01:33AM Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years
Sep 19, 2016 01:22AM Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
View More Recent Stories View Older Stories